2000; Laughner et al. 2001). Specifically, the PI3K/AKT/mTOR pathway, which is activated in the vast majority of human cancers (Hennessy et al. 2005; Danielsen et al. 2015; Vara et al. 2004; Malinowsky et al. 2014; Wang et al. 2013), and seen to instigate the glycolytic activity of cancer cells by upregulating the hypoxia-inducible factor 1 (HIF1) and its downstream targets (Cairns et al. 2011; Valvona et al. 2016; Laughner et al. 2001; Zhong et al. 2000). The gene discussed is MTOR; the disease is cancer.